Close

News Releases

News Release

Meridian Bioscience Again Recognized by Forbes as One of the 200 Best Small Companies

October 21, 2004 at 10:37 AM EDT

CINCINNATI--(BUSINESS WIRE)--Oct. 21, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has been recognized by Forbes as one of "The 200 Best Small Companies" for the second year in a row. The 200 Best Small Companies list is selected following a comprehensive evaluation of financial results plus additional operating factors of candidate companies having sales between $5 million and $750 million. Additional qualification criteria included a consistent pattern of positive growth during a five-year period as well as over the last twelve months, net profit margins greater than 5% and share prices above $5.00. Meridian Bioscience's overall ranking was 137 and, in the individual category rankings, Meridian was 33rd based upon its five-year average return on equity.

John A. Kraeutler, President and Chief Operating Officer, stated, "We are delighted to have been recognized, once again, by Forbes magazine as one of The 200 Best Small Companies for the past year. This recognition is a credit to all of Meridian's employees, our loyal customers, and our distribution partners around the world. We will continue our focused approach to provide products and technologies that aid in the diagnosis and management of common diseases."

Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral, urinary and respiratory infections. All Meridian diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents and specialty biologicals along with proteins and other biologicals used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices and diagnostics manufacturers in more than 60 countries around the world. The Company's shares are traded through Nasdaq's National Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.


    CONTACT: Meridian Bioscience, Inc.
             John A. Kraeutler, 513-271-3700

    SOURCE: Meridian Bioscience, Inc.